Indivior Pharmaceuticals, Inc. (INDV) Form 8-K — Nov 2, 2026
Indivior Pharmaceuticals and Supernus Pharmaceuticals completed their merger effective 8:18 a.m. ET on November 2, 2026, with Supernus surviving as a wholly owned subsidiary of Indivior, which was immediately renamed Supernus, Inc. Each Supernus share converted into 1.5401 Indivior shares, leaving legacy Indivior stockholders with approximately 56.5% and former Supernus stockholders with approximately 43.5% of the combined company on a fully diluted basis. The combined company entered a $650 million senior secured term loan facility with Citibank as agent to fund the merger, refinance existing debt, and cover transaction costs, bearing interest at Term SOFR plus 2.25% initially.
Key figures
- Debt Amount
- 650000000
- Interest Rate
- Term SOFR + 2.25% initially; thereafter Term SOFR + 2.00%-2.75% or Base Rate + 1.00%-1.75% based on leverage
- Maturity
- earlier of fifth anniversary of Effective Date or 91 days prior to Convertible Notes maturity
- Board size
- 8
- Exchange ratio
- 1.5401 Indivior shares per Supernus share
- Khattar base salary
- $1,115,000
- Former supernus ownership
- approximately 43.5% fully diluted
- Legacy indivior ownership
- approximately 56.5% fully diluted
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.